Top 5 Stock Picks of Joel Ramin’s 12 West Capital

4. Repligen Corporation (NASDAQ:RGEN)

Mr. Ramin’s Stake Value: $214 million

Percentage of Mr. Ramin’s 13F Portfolio: 8.99%

Number of Hedge Fund Holders: 35

Repligen Corporation (NASDAQ:RGEN) manufactures and sells technologies and systems for biological drug manufacturing. The company offers protein ligands, chromatography and filtration products.

By the end of the second quarter, Mr. Ramin held one million shares of Repligen Corporation (NASDAQ:RGEN) in a stake that is worth $214 million and represents 8.99% of his portfolio. The company earned $178 million in revenue and $0.78 in non-GAAP EPS in its third quarter, beating analyst estimates on both counts.

In an September 2021 investment note, Craig-Hallum raised Repligen Corporation’s (NASDAQ:RGEN) price target to $368 sharing that the company’s protein segment is set to benefit in the wake of the ongoing pandemic. Insider Monkey’s second quarter survey of 873 hedge funds revealed that 35 held a stake in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation (NASDAQ:RGEN)’s largest stakeholder is Robert Joseph Caruso’s Select Equity Group who owns 1.2 million shares worth $258 million.

In its third-quarter 2021 investor letter, Alger, an investment management firm mentioned Repligen Corporation (NASDAQ:RGEN) and stated:

Repligen Corporation was among the top contributors to performance. Repligen is aleading provider of advanced bioprocessing technologies and solutions used in manufacturing biologic drugs. Repligen’s main product areas are in filtration, which involves removing cellular metabolic waste during fermentation; chromatography, which purifies the final biologic drugs; growth factor products, which are used during manufacturing; and process analytics, which is used to analyze the purity of drug substances. The performance of Repligen shares benefited from the company announcing in July that it generated strong second quarter results. Repligen posted impressive organic growth resulting from strong demand for its core products and COVID-19 vaccine manufacturing. In addition, Repligen closed the acquisition of Polymem SA in July to significantly expand its filtration manufacturing capacity and add new technologies. The company also announced the acquisition of Avitidei, which could strengthen its protein and growth factor business.”